Large-Scale Real-World Study Demystifies UroLift System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal Prostate Cancer and Prostatic Diseases reinforces the position of the UroLift System as the gold standard in minimally invasive surgical treatment (MIST) for benign prostatic hyperplasia (BPH), or enlarged prostate. Retreatment Rates and Postprocedural Complications Are Higher Than Expected After BPH Surgeries: A U.S. Healthcare Claims and Utilization Study is the largest longitudinal healthcare claims study evaluating complication and retreatment rates after BPH treatment with leading surgical and MIST ever conducted, and the only study to include all outpatient sites of service.¹

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies. However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies. This first-of-its-kind study overcomes these limitations and directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments. Results suggest that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of whether they receive a transurethral resection of the prostate (TURP), GreenLight photoselective vaporization of the prostate (PVP), Rezūm water vapor thermal therapy (WVTT) or UroLift System prostatic urethral lift (PUL) (5.9% UroLift PUL, 5.3% TURP, 5.3% GreenLight PVP, 6.2% Rezūm WVTT; rates are not statistically different). At five years, retreatment was lowest for TURP (7.0%) and statistically similar between GreenLight PVP and the UroLift System (8.9% and 11.6% respectively).* The retreatment rate for UroLift PUL (11.6%) is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift System.

“With this large-scale analysis, we aimed to provide a way for urologists and patients to understand retreatment for BPH therapies in a real-world setting,” said Steven Kaplan, MD, professor of Urology, Icahn School of Medicine at Mount Sinai, director of the Men’s Health Program at Mount Sinai Health System, New York, and lead author on the paper. “To my knowledge, it is the first time a uniform definition for retreatment has been applied to all the technologies. Perhaps what is most striking is the elevated rate of surgical retreatment occurring after TURP and GreenLight PVP within the first year.”